Rafael Holdings Inc
RFL
查看详细走势图
1.220USD
+0.050+4.24%
收盘 02/06, 16:00（美东）报价延迟15分钟
63.92M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.24%
5天
+5.17%
1月
-6.15%
6月
-27.38%
今年开始到现在
+3.39%
1年
-39.63%
查看详细走势图
TradingKey Rafael Holdings Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Rafael Holdings Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名119/159位。机构持股占比非常高，中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Rafael Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Rafael Holdings Inc亮点
亮点风险
Rafael Holdings, Inc. is a biotechnology company. The Company holds interests in clinical and early-stage pharmaceutical companies, including a 100% interest in Cyclo Therapeutics, LLC, a biotechnology company focusing on developing its lead clinical candidate, Trappsol Cyclo, which is being evaluated in clinical trials, including an ongoing Phase III trial for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal, and progressive genetic disorder. It also holds an interest in LipoMedix Pharmaceuticals Ltd., a clinical-stage pharmaceutical company; Barer Institute Inc., a wholly owned preclinical cancer metabolism research operation, and an interest in Cornerstone Pharmaceuticals, Inc., a cancer metabolism-based therapeutics company. It holds an interest in Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and a majority interest in Day Three Labs, Inc.
业绩高增长
公司营业收入稳步增长，连续3年增长228.67%
业绩增长期
公司处于发展阶段，最新年度总收入917.00K美元
利润高增长
公司净利润处于行业前列，最新年度总收入917.00K美元
估值合理
公司最新PE估值-1.45，处于3年历史合理位
机构减仓
最新机构持股3.73M股，环比减少18.90%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值76.43K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.03
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Rafael Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Rafael Holdings Inc简介
Rafael Holdings, Inc. is a biotechnology company. The Company holds interests in clinical and early-stage pharmaceutical companies, including a 100% interest in Cyclo Therapeutics, LLC, a biotechnology company focusing on developing its lead clinical candidate, Trappsol Cyclo, which is being evaluated in clinical trials, including an ongoing Phase III trial for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal, and progressive genetic disorder. It also holds an interest in LipoMedix Pharmaceuticals Ltd., a clinical-stage pharmaceutical company; Barer Institute Inc., a wholly owned preclinical cancer metabolism research operation, and an interest in Cornerstone Pharmaceuticals, Inc., a cancer metabolism-based therapeutics company. It holds an interest in Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and a majority interest in Day Three Labs, Inc.
公司代码RFL
公司Rafael Holdings Inc
CEOJonas (Howard S)
网址https://rafaelholdings.com
相关品种
